BiotechTube

Adalimumab originator + Adalimumab biosimilar

Phase 3Completed
0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Plaque Psoriasis

Conditions

Plaque Psoriasis

Trial Timeline

Jun 30, 2020 → Nov 16, 2021

NCT ID
NCT04453137

About Adalimumab originator + Adalimumab biosimilar

Adalimumab originator + Adalimumab biosimilar is a phase 3 stage product being developed by Alvotech for Plaque Psoriasis. The current trial status is completed. This product is registered under clinical trial identifier NCT04453137. Target conditions include Plaque Psoriasis.

What happened to similar drugs?

20 of 20 similar drugs in Plaque Psoriasis were approved

Approved (20) Terminated (6) Active (0)
✅alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅alefaceptAstellas PharmaApproved
✅AlefaceptAstellas PharmaApproved
✅Halobetasol Topical LotionSun PharmaceuticalApproved
✅Topicort® (desoximetasone) Topical Spray, 0.25%Sun PharmaceuticalApproved
✅KHK4827-Active + KHK4827-PlaceboKyowa KirinApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT04453137Phase 3Completed

Competing Products

20 competing products in Plaque Psoriasis

See all competitors
ProductCompanyStageHype Score
CT-P17 + EU-approved HumiraCelltrionPhase 3
40
CT-P55 + EU-approved CosentyxCelltrionPhase 3
44
alefacept + polyvalent pneumococcal vaccineAstellas PharmaApproved
43
alefaceptAstellas PharmaPhase 3
40
Amevive exposureAstellas PharmaPre-clinical
18
alefacept + placeboAstellas PharmaPhase 3
40
alefaceptAstellas PharmaApproved
43
alefaceptAstellas PharmaApproved
35
AlefaceptAstellas PharmaApproved
43
Halobetasol PropionateSun PharmaceuticalPhase 2
27
Placebo + SCD-044_Low Dose (Dose 1) + SCD-044_Intermediate Dose (Dose 2) + SCD-044_High Dose (Dose 3)Sun PharmaceuticalPhase 2
35
DSXS + PlaceboSun PharmaceuticalPhase 3
40
DSXSSun PharmaceuticalPhase 2
35
DSXS topicalSun PharmaceuticalPhase 2
35
Halobetasol Topical LotionSun PharmaceuticalApproved
35
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Matching PlaceboSun PharmaceuticalPhase 3
40
DSXS1411 + PlaceboSun PharmaceuticalPhase 2
35
Tildrakizumab + PlaceboSun PharmaceuticalPhase 3
40
Tildrakizumab 200 mg + Tildrakizumab 100 mg + Tildrakizumab Placebo + Etanercept Placebo + Etanercept 50 mgSun PharmaceuticalPhase 3
40
MK-3222 200 mg + MK-3222 100 mg + Placebo to MK-3222 + Placebo to Etanercept + Etanercept 50 mgSun PharmaceuticalPhase 3
32